» Articles » PMID: 12142567

A Potent Protective Role of Lysophospholipids Against Global Cerebral Ischemia and Glutamate Excitotoxicity in Neuronal Cultures

Overview
Publisher Sage Publications
Date 2002 Jul 27
PMID 12142567
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Lysophospholipids (LPLs) are important intermediates in the synthesis and degradation of membrane phospholipids. Here we show that certain LPLs, particularly lysophosphatidylcholine and lysophosphatidylinositol, prevent neuronal death both in an in vivo model of transient global ischemia and in an in vitro model of excitotoxicity using primary cultures of cerebellar granule cells exposed to high extracellular concentrations of glutamate (20-40 micromol/L). The intravenous injection of lysophosphatidylcholine or lysophosphatidylinositol at a concentration of 200 nmol/kg induced a survival of CA1 pyramidal neurons as high as approximately 95%, even when the treatment was started 30 minutes after 15-minute global ischemia. In contrast, lysophosphatidic acid induced no protection. This work also provides evidence that a pretreatment with lysophosphatidylcholine or lysophosphatidylinositol (200 nmol/kg) injected as long as 3 days before a severe 6-minute ischemia provided a potent tolerance against neurodegeneration. Neuroprotection was also observed in in vitro experiments with LPLs. Taken together, in vivo and in vitro data suggest a potential therapeutic use of LPLs as antiischemic compounds. The potential role of 2P-domain K+ channels as targets of LPLs in this potent neuroprotective effect is discussed.

Citing Articles

Multi-omics Study of Hypoxic-Ischemic Brain Injury After Cardiopulmonary Resuscitation in Swine.

Yu S, Xu J, Wu C, Zhu Y, Diao M, Hu W Neurocrit Care. 2024; 42(1):59-76.

PMID: 38937417 DOI: 10.1007/s12028-024-02038-7.


Comprehensive evaluation of Dragon's Blood in combination with borneol in ameliorating ischemic/reperfusion brain injury using RNA sequencing, metabolomics, and 16S rRNA sequencing.

Ren J, Zhang X, Zhou L, Cao W, Zhang L, Chen X Front Pharmacol. 2024; 15:1372449.

PMID: 38783945 PMC: 11112420. DOI: 10.3389/fphar.2024.1372449.


Diagnosing Parkinson's disease and monitoring its progression: Biomarkers from combined GC-TOF MS and LC-MS/MS untargeted metabolomics.

Dahabiyeh L, Nimer R, Wells J, Abu-Rish E, Fiehn O Heliyon. 2024; 10(9):e30452.

PMID: 38720721 PMC: 11077040. DOI: 10.1016/j.heliyon.2024.e30452.


Protective effect and mechanism of styrax on ischemic stroke rats: metabonomic insights by UPLC-Q/TOF-MS analysis.

Mu F, Lin R, Lu X, Zhao M, Zhao J, Huang S Pharm Biol. 2023; 61(1):1318-1331.

PMID: 37621078 PMC: 10461497. DOI: 10.1080/13880209.2023.2246501.


Acute effects of single and repeated mild traumatic brain injury on levels of neurometabolites, lipids, and mitochondrial function in male rats.

Allen J, Pham L, Bond S, OBrien W, Spitz G, Shultz S Front Mol Neurosci. 2023; 16:1208697.

PMID: 37456524 PMC: 10338885. DOI: 10.3389/fnmol.2023.1208697.